Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-Claudin 18.2 CAR-T cell therapy - First Affiliated Hospital Xi'an Jiaotong University

Next Previous
Drug Profile

Anti-Claudin 18.2 CAR-T cell therapy - First Affiliated Hospital Xi'an Jiaotong University

Alternative Names: Anti-Claudin 18.2 chimeric antigen receptor T cell therapy - First Affiliated Hospital Xi'an Jiaotong University; LCAR-C182A/LCAR-C182B/LCAR-C182C cells

Latest Information Update: 28 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator First Affiliated Hospital-Xi'an Jiaotong University
  • Developer First Affiliated Hospital-Xi'an Jiaotong University; Nanjing Legend Biotech
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Gastric cancer; Pancreatic cancer

Most Recent Events

  • 28 May 2022 No recent reports of development identified for phase-I development in Gastric-cancer(Inoperable/Unresectable, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
  • 28 May 2022 No recent reports of development identified for phase-I development in Pancreatic-cancer(Inoperable/Unresectable, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
  • 02 Jul 2020 First Affiliated Hospital Xi'an Jiaotong University and Nanjing Legend Biotech terminates phase I trial in Gastric cancer and pancreatic cancer due to the preliminary data, progress of this study and the adjustment of the pipeline and strategy in China (NCT03890198)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top